Bridge Biotherapeutics announced on the 3rd that it will send a business trip team, including CEO Lee Jung-kyu and business development executives, to the '2024 JP Morgan Healthcare Conference (JPMHC)' held in San Francisco, California, USA from the 8th to the 11th.
During the JPMHC, the company plans to meet with representatives from global pharmaceutical and biotech companies to explore opportunities for technology transfer related to its core research and development (R&D) projects, as well as to seek partnerships for new cancer combination therapies. While the global Phase 2 clinical trial of 'BBT-877,' being developed as a treatment for idiopathic pulmonary fibrosis, is underway, the company will hold one-on-one face-to-face meetings with top global pharmaceutical companies under confidentiality agreements (CDA) to advance discussions.
In addition, strategic discussions for the global and regional rights transfer of 'BBT-207,' a targeted therapy for non-small cell lung cancer with active patient clinical trials, are expected to begin in earnest.
Meetings will also be held to attract investment for the expansion and establishment of an independent operational system of the local research corporation, Boston Discovery Center (BDC), established in Boston, USA in 2021. Christopher Kim, head of the US corporation, will lead the investment attraction for the independent branding of BDC.
Lee Jung-kyu, CEO of Bridge Biotherapeutics, said, “We plan to make relentless efforts to start 2024 vigorously at JPMHC,” adding, “Since various discussions with global pharmaceutical and biotech companies are scheduled locally, we will strive to deliver results as soon as possible.”
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
